The Swedish pharmaceutical company Moberg Derma, which focuses on skin diseases, is today reporting positive data from its clinical phase II trial involving the K301 product candidate. K301, which is based on the patented Kaprolac® principle, is a new non-steroid topical treatment for seborrheic dermatitis of the scalp. In the trial, two different formulations of K301 were tested against placebo. 76 percent of patients who received the selected K301 formulation responded positively to the treatment. Moberg Derma plans to conduct a phase III clinical trial for K301 with the goal to reach the market in 2009.
